FDA, HIV and Gilead
FDA sets June date for Gilead's twice-yearly HIV PrEP
Analysts at RBC Capital Markets have predicted twice-yearly lenacapavir could become a $2 billion product, and become a key component of Gilead's PrEP franchise as it tries to ward off a challenge from HIV market rival ViiV Healthcare, majority owned by GSK.
Gilead Gets FDA Priority Review of Twice-Yearly Shot to Prevent HIV
Gilead Sciences has won Food and Drug Administration priority review for its proposed lenacapavir twice-yearly shot to prevent HIV. Gilead on Tuesday said an FDA green light would make lenacapavir the first and only twice-yearly drug for the prevention of HIV as pre-exposure prophylaxis.
This was the stock's third consecutive day of gains.
Assembly Biosciences (ASMB) announced promising interim results from its ongoing Phase 1a/b study of ABI-1179, an ...
We recently published a list of 10 Stocks That Analysts Think Will Go Up. In this article, we are going to take a look at ...
Gilead Sciences has defied analysts’ expectations by passing on its chance to license Arcus Biosciences’ potential rival to Merck & Co.’s kidney cancer drug Welireg.
Gilead (GILD) stock won an upgrade from Deutsche Bank on HIV treatment boost, while Merck (MRK) stock received a downgrade on ...
Shares of Gilead Sciences ( GILD -1.77%) were jumping 7.9% higher on Wednesday at 11:34 a.m. The solid gain came after the ...
Deutsche Bank upgraded Gilead (GILD) to Buy from Hold with a price target of $120, up from $80. The company’s core HIV treatment franchise ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback